Preclinical investigations revealed that RASi ameliorate proteinuria and tubulointerstitial fibrosis not merely through blood pressure reduction but via molecular interventions such as NF-κB pathway inhibition and attenuation of macrophage infiltration, effectively counteracting inflammatory and fibrotic processes in DKD [152]. Here, NFKB1 is linked to diabetic kidney disease.